



Fiscal 2023 Q2 Earnings Call

December 15, 2022
ipatherapeutics.com
NASDAQ: IPA



Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.


The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Further information on risks and uncertainties may be found in the Company’s Management Discussion & Analysis which may be obtained from SEDAR at www.sedar.com and SEC at www.sec.gov.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Fiscal 2023 Q2 Business Update

YTD % Change Share Price, IPA vs Peers




Newest Commercial Services, BioStrand

Fee-for-Service Offerings


- *In silico* immunogenicity analysis
- Epitope mapping
- Off-target analysis
- NLP-driven target analysis

Early Adopter Services – Milestone Driven

- Epitope-Paratope
- Paratope-Paratope



Organoids Market Size, 2021 to 2030 (USD Billion)




Talem Updates



TATX-03 PolyTope®



Application(s)/ problem to be solved	Latest milestone reached	Value proposition/ differentiator(s)	Next steps/ commercialization plan
SARS-CoV-2 therapeutic with resilience against all variants	• Start-up Agreement completed with clinical CRO • Clinical study design finalized • Vendor selected for bioassays clinical samples • Finalizing clinical trial CRO agreements	• Superior to authorized therapies as demonstrated by its broadly neutralizing capacity of VOCs • Four antibody combination • Strong positive EMA regulatory feedback • Market longevity upon authorization	• Expecting Phase 1/2a clinical material before end of the year • Start FIH Spring 2023 • Leveraging antibody therapy commercialization expertise of KOL to support business development efforts





TATX-112 & TATX-24: TrkB T-cell engagers

Application(s)/ problem to be solved	Latest milestone reached	Value proposition/ differentiator(s)	Next steps/ commercialization plan
Solid tumors such as breast, colon and lung cancer	- Bispecifics-demonstrated activation and preliminary bispecific proof-of-concept Provisional patent filed to protect both assets and corresponding bispecifics and support out licensing	- Potential first-in-class antibody therapy - Potential best-in-class therapeutic - TrkB is expressed in wide range of solid tumors with no/minimal expression in healthy tissue - Unique T-cell activation profile compared to commercially available benchmark	<i>In vitro</i> characterization data package <i>Ex/in vivo</i> proof of concept of solid tumor clearance

Accelerator Building

Utrecht, The Netherlands




- **2x lab space**
- **Expanded protein production capacity and capabilities**




Fiscal 2023 Q2 Financial Update




Trends in Revenue and Gross Profit



Changes in Operating Expenses




Changes in Other Income (Expense)






Changes in Net Loss



Changes in Cash Balance






Fiscal 2023 Q2 Earnings Call

December 15, 2022
ipatherapeutics.com
NASDAQ: IPA





Thank you



Thank you

Engineered for the race
and the shared pursuit
of clinical success

www.ipatherapeutics.com

NASDAQ: IPA